Vera Therapeutics Sees Major Price Target Hikes as Analysts Bet Big on Its Kidney Disease Drug
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.